Intercepting Blood Cancers

14 - 16 March, 2024

Lisbon, Portugal

The 2024 Intercepting Blood Cancers Workshop (IBC) will provide a unique, interactive platform for presentations on key clinical trial data and expert clinical insights for early interventions in blood cancers and how this impacts outcomes for patients; three key topic tracks will include:

  • Lymphoma, chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis (MBL)
  • Multiple myeloma, smoldering myeloma (SMM) and monoclonal gammopathy of unknown significance (MGUS)
  • Clonal hematopoiesis of indeterminate potential (CHIP), Myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and clonal cytopenia of undetermined significance (CCUS)
The current aims of the workshop are to:
  • Describe current knowledge of blood cancer precursors and how these might enable early clinical intervention
  • Discuss ongoing clinical studies and any available data from these on treatment interceptions for early-stage blood cancers
  • Share knowledge and clinical insights between blood cancer disciplines and therapy areas
  • Plan for publication and dissemination of consensus findings from discussions across each of the key topic tracks
striped logostriped logooutlined logo
location

Supporter Opportunities

If you are interested in becoming a supporter of the IBC meeting, please contact us

striped circlestriped circlestriped circlestriped logo

The IBC 2024 Workshop is supported by:

Platinum Supporters

Gold Supporters

Silver Supporters

Bronze Supporters